<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617002</url>
  </required_header>
  <id_info>
    <org_study_id>ONC028</org_study_id>
    <nct_id>NCT04617002</nct_id>
  </id_info>
  <brief_title>Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas</brief_title>
  <official_title>Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <brief_summary>
    <textblock>
      This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3&#xD;
      K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Glioma</condition>
  <condition>H3 K27M</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONC201</intervention_name>
    <description>ONC201 is an oral, small molecule selective antagonist of DRD2</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient meet one or more of the criteria below:&#xD;
&#xD;
             Arm A&#xD;
&#xD;
               1. Central nervous system tumor that is positive for the H3 K27M mutation (performed&#xD;
                  in a laboratory with CLIA or equivalent certification);&#xD;
&#xD;
               2. Central nervous system tumor involving the thalamus, hypothalamus, basal ganglia,&#xD;
                  brainstem, cerebellum, cerebellar peduncle, midline cortex, corpus callosum,&#xD;
                  pineal region, optic tract, or optic chiasm.&#xD;
&#xD;
                  Arm B&#xD;
&#xD;
               3. Diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine&#xD;
                  epicenter and diffuse involvement of the pons. H3 K27M status does not have to be&#xD;
                  known or positive for this arm.&#xD;
&#xD;
          2. Arm A: Patient must have unequivocal radiographic evidence of progressive disease on&#xD;
             as defined by RANO criteria or have documented recurrent glioma on diagnostic biopsy.&#xD;
&#xD;
             Arm B: Patient are not required to have radiographic or clinical evidence of&#xD;
             progressive disease.&#xD;
&#xD;
          3. Arm A: Patient must be at least 90 days from completion of radiotherapy. Arm B:&#xD;
             Patient must be at least 14 days from completion of radiotherapy.&#xD;
&#xD;
          4. Patient must be at least 2 years of age.&#xD;
&#xD;
          5. Patient must weigh at least 10kg.&#xD;
&#xD;
          6. From the projected start of scheduled study treatment, the following time periods must&#xD;
             have elapsed from prior anti-cancer treatments: 5 half-lives from any investigational&#xD;
             agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks&#xD;
             from nitrosoureas), 6 weeks from anti-cancer antibodies (except 21 days for&#xD;
             bevacizumab), 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor&#xD;
             therapies, and 1 week from devices used to treat cancer.&#xD;
&#xD;
          7. Brain MRI within 21 days prior to start of study drug.&#xD;
&#xD;
          8. Adequate organ and marrow function as defined below:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to&#xD;
                  treatment (cycle 1 day 1, C1D1)&#xD;
&#xD;
               2. Hemoglobin &gt;8.0 mg/dL without red blood cell transfusion ≤ 3 days prior to C1D1&#xD;
&#xD;
               3. Total serum bilirubin &lt;1.5 X upper limit of normal (ULN)&#xD;
&#xD;
               4. AST (SGOT)/ALT (SGPT) ≤2 X ULN; ≤ 5 X ULN if there is liver involvement secondary&#xD;
                  to tumor&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2)&#xD;
&#xD;
          9. For patients post pubertal: Female patients must agree to use effective contraception&#xD;
             while taking ONC201 and for at least 90 days after completion of treatment. Male&#xD;
             patients must be surgically sterile or must agree to use effective contraception while&#xD;
             taking ONC201 and for at least 90 days after completion of treatment. The decision of&#xD;
             effective contraception will be based on the judgment of the principal investigator.&#xD;
&#xD;
         10. Ability to understand a written informed consent document, and the willingness to sign&#xD;
             it. Assent will be obtained when appropriate based on the subjects age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Qualifies for participation in an ongoing ONC201 or ONC206 clinical trial.&#xD;
&#xD;
          2. Previously or currently participating in an ONC201 clinical trial.&#xD;
&#xD;
          3. Current or planned participation in a study of an investigational agent (including&#xD;
             ONC206) or using an investigational device.&#xD;
&#xD;
          4. Evidence of leptomeningeal disease or CSF dissemination of disease.&#xD;
&#xD;
          5. Any known systemic infection that, in the opinion of the investigator, could&#xD;
             compromise the safety of the patient, while taking ONC201.&#xD;
&#xD;
          6. Prolongation of QT/QTcF interval (QTc interval &gt;480 milliseconds) using Frederica's QT&#xD;
             correction formula on two ECGs separated by at least 48 hours.&#xD;
&#xD;
          7. A history of Torsades de Pointes or heart failure, hypokalemia, or family history of&#xD;
             prolonged QT Syndrome&#xD;
&#xD;
          8. Concomitant use of medication(s) known to prolong the QT/QTc interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Rohinton Tarapore, PhD</last_name>
    <phone>1-919-806-1074</phone>
    <email>rtarapore@chimerix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Felkins</last_name>
    <phone>1-919-806-1074</phone>
    <email>afelkins@chimerix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Megan Paul, MD</last_name>
      <email>mrpaul@rchsd.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Akanksha Sharma, MD</last_name>
      <email>Akanksha.Sharma@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Ashley Mettetal</last_name>
      <phone>720-777-5305</phone>
      <email>Ashley.Mettetal@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen Dorris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Lindsay Kilburn, MD, MS</last_name>
      <phone>202-476-3643</phone>
      <email>LKilburn@childrensnational.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Yazmin Odia, MD, MS</last_name>
      <phone>786-596-2000</phone>
      <email>DG-MCIResearchNurses@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Yazmin Odia, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ON HOLD: (currently not accepting new patients) Children's Healthcare of Atlanta, Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Dolly Aguilera, MD</last_name>
      <phone>404-785-1112</phone>
      <email>AflacDevTReferral@choa.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kapi'olani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Andrea Siu, MPH</last_name>
      <phone>808-535-7169</phone>
      <email>Andrea.siu@hawaiipacifichealth.org</email>
    </contact>
    <investigator>
      <last_name>Kelley Hutchins, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Mariko Sato, MD, PhD</last_name>
      <email>mariko-sato@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Misty Gravelin</last_name>
      <phone>734-763-0592</phone>
      <email>gravelim@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Carl Koschmann, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Andrew Cluster, MD</last_name>
      <email>acluster@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alison Barnwell</last_name>
      <email>abarnwell@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Cluster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center/ Atlantic Health System</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jeanna Johnson</last_name>
      <phone>973-829-4869</phone>
      <email>Jeanna.Johnson@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Aiken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sharon Gardner, MD</last_name>
      <phone>646-929-7870</phone>
      <email>Sharon.Gardner@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Anna Yaffe</last_name>
      <phone>212-263-9945</phone>
      <email>anna.yaffe@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sharon Gardner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>David Korones, MD</last_name>
      <phone>585-275-2981</phone>
      <email>David_korones@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Serventi, PA</last_name>
      <phone>585-275-5863</phone>
      <email>Jennifer_serventi@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Alison Patterson</last_name>
      <phone>214-456-2726</phone>
      <email>alison.patterson@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Bowers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Melissa Mark, MD</last_name>
      <email>Melissa.Mark@CHKD.ORG</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>TIC10 compound</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

